Generics - Dr Reddy's Laboratories


Current filters:

Dr Reddy's Laboratories

Popular Filters

1 to 25 of 31 results

Dr Reddy’s sees generics soar due to limited competition

Dr Reddy’s sees generics soar due to limited competition


India’s second-largest drugmaker Dr Reddy's Laboratories has reported strong third quarter sales of…

Dr Reddy's LaboratoriesFinancialGenericsIndiaPharmaceutical

Dr Reddy's 1st-qtr misses expectations


India's second largest drugmaker Dr Reddy's Laboratories (NYSE: RDY) has posted its unaudited consolidated…

Dr Reddy's LaboratoriesFinancialGenerics

Leading Indian drugmakers eye pharma production in Russia


Several top Indian drugmakers and suppliers, including Dr Reddy's (NYSE: RDY), Ranbaxy (BSE: 500359),…

Asia-PacificAurobindo PharmaCiplaDr Reddy's LaboratoriesEuropeGenericsProductionRanbaxy Laboratories

Generic launches by Mylan, Stada Arz and Dr Reddy's


US copy drugs maker Mylan (NYSE: MYL) has launched norethindrone tablets USP, 0.35 the generic version…

Dr Reddy's LaboratoriesEuropeGenericsLamictal XRMarkets & MarketingMen's HealthMicronorMylan LaboratoriesNeurologicalNorth AmericaReproductiveSTADA ArzneimittelViagra

Fujifilm and Dr Reddy's abandon plans for generics JV in Japan


Japan's Fujifilm Corp and Indian drugmaker Dr Reddy's Laboratories (NYSE: RDY) have decided to terminate…

Dr Reddy's LaboratoriesFujifilmGenericsMergers & AcquisitionsProduction

Dr Reddy's 2012 revenues grew 20%, with earnings up 24%


Dr Reddy's Laboratories (NYSE: RDY), India's second largest drugmaker, has announced its audited consolidated…

Dr Reddy's LaboratoriesFinancialGenerics

News briefs: Dr Reddy's launches generic Accutane; Cyprus drug shortages


Indian drugmaker Dr Reddy's Laboratories (NYSE: RDY) says it launched Zenatane (isotretinoin capsules…

AccutaneDermatologicalsDr Reddy's LaboratoriesEuropeGenericsHealthcareMarkets & MarketingNorth AmericaPharmaceuticalZenatane

Dr Reddy's in $22.5 million settlement with Nordion


India's second largest drugmaker Dr Reddy's Laboratories (NYSE: RDY) said last Friday (March 22) that…

Dr Reddy's LaboratoriesFinancialGenericsLegalNordion

Watson Pharma now trading as Actavis; Dr Reddy's debuts generic Clarinex Reditabs in USA


US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) announced last week that the company has adopted…

ActavisClarinex ReditabsDr Reddy's LaboratoriesFinancialGenericsManagementMarkets & MarketingWatson Pharmaceuticals

Dr Reddy's beats forecasts with 27% revenue growth and 47% EBITDA rise


India's second largest drugmaker by sales, Dr Reddy's Laboratories (NYSE: RDY), yesterday announced its…

Dr Reddy's LaboratoriesFinancialGenerics

India's Dr Reddy's to acquire OctoPlus for $35.7 million


India's second largest drugmaker Dr Reddy's Laboratories (NYSE: RDY) announced this morning that it intendeds…

Dr Reddy's LaboratoriesGenericsMergers & AcquisitionsOctoPlusPharmaceutical

"Sandoz will be the leading biosimilars company in 2012," says Visiongain


Sandoz, the generics unit of Swiss drug major Novartis (NVN: VX), will retain its position as the global…

BiotechnologyDr Reddy's LaboratoriesGenericsGlobalHospiraMarkets & MarketingNovartisSandoz

Dr Reddy's posts 28% revenue growth for fiscal 1st-qtr 2013


India's second largest drugmaker Dr Reddy's Laboratories (NYSE: RDY) yesterday released unaudited consolidated…

Dr Reddy's LaboratoriesFinancialGenerics

Merck KGaA collaborates with Dr Reddy's on biosimilars


With the aim of capitalizing on the batch of patent expires for blockbuster biotechnology-based drugs…

BiotechnologyDr Reddy's LaboratoriesGenericsMarkets & MarketingMerck KGaAMerck SeronoOncologyResearch

US FDA approves generic versions of blood thinner Plavix


Coinciding with the loss of patent protection on Sanofi (Euronext: SAN) and Bristol-Myers Squibb's (NYSE:…

Cardio-vascularClopidogrelDr Reddy's LaboratoriesGenericsMylan LaboratoriesNorth AmericaPlavixRegulation

Dr Reddy's sees FY2011/12 sales rise 30%


India's second-largest drugmaker, Dr Reddy's Laboratories (NYSE: RDY) posted full year ended March 31,…

Dr Reddy's LaboratoriesFinancialGenerics

Dr Reddy’s beats forecasts, with 88% profits hike


India drug major Dr Reddy’s Laboratories (500124: BO) saw its shares rise 2.2% to 1,670.50 rupees…

Dr Reddy's LaboratoriesFinancialGenerics

1 to 25 of 31 results

Back to top